This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

DexCom Inc. Reports Third Quarter 2011 Financial Results

Stocks in this article: DXCM

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the participant code "28602165" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company’s products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company’s inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ended September 30, 2011, as filed with the Securities and Exchange Commission on November 2, 2011.

   
DexCom, Inc.
Consolidated Balance Sheets
(In thousands—except par value data)
 

September 30, 2011 (Unaudited)

 

December 31, 2010
Assets
Current assets:
Cash and cash equivalents $ 17,523 $ 4,889
Short-term marketable securities, available-for-sale 79,794 42,224
Accounts receivable, net 9,003 6,671
Inventory 6,455 8,112
Restricted cash 0 775
Prepaid and other current assets   2,457     2,690  
 
Total current assets 115,232 65,361
Property and equipment, net 12,524 10,763
Restricted cash 939 939
Other assets   98     101  
 
Total assets $ 128,793   $ 77,164  
 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities $ 6,045 $ 5,350
Accrued payroll and related expenses 6,961 5,730
Current portion of long-term debt 0 525
Current portion of deferred revenue   1,737     3,524  
 
Total current liabilities 14,743 15,129
Other liabilities   985     1,042  
 
Total liabilities 15,728 16,171
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively 0 0
Common stock, $0.001 par value, 100,000 authorized; 67,783 and 67,500 issued and outstanding, respectively, at September 30, 2011; and 62,360 and 62,078 shares issued and outstanding, respectively, at December 31, 2010 68 62
Additional paid-in capital 491,964 407,375
Accumulated other comprehensive loss (94 ) (66 )
Accumulated deficit   (378,873 )   (346,378 )
 
Total stockholders’ equity   113,065     60,993  
 
Total liabilities and stockholders’ equity $ 128,793   $ 77,164  
 
       
DexCom Inc.
Consolidated Statements of Operations
(In thousands—except per share data)
(Unaudited)
 
Three Months Ended September 30, Nine Months Ended September 30,
  2011     2010     2011     2010  
Product revenue $ 16,656 $ 10,776 $ 44,974 $ 26,583
Development grant and other revenue   1,598     888     8,871     6,412  
 
Total revenue 18,254 11,664 53,845 32,995
Product cost of sales 9,230 6,982 25,933 18,440
Development and other cost of sales   860     1,206     2,761     3,101  
 
Total cost of sales   10,090     8,188     28,694     21,541  
 
Gross profit 8,164 3,476 25,151 11,454
Operating expenses
Research and development 8,231 6,161 21,515 16,325
Selling, general and administrative   13,241     10,377     36,203     30,533  
 
Total operating expenses 21,472 16,538 57,718 46,858
Operating loss (13,308 ) (13,062 ) (32,567 ) (35,404 )
Interest income 31 20 82 73
Interest expense (1 ) (44 ) (10 ) (1,540 )
Loss on debt extinguishment upon conversion of convertible debt   0     (312 )   0     (8,487 )
 
Net loss $ (13,278 ) $ (13,398 ) $ (32,495 ) $ (45,358 )
 
Basic and diluted net loss per share $ (0.20 ) $ (0.23 ) $ (0.50 ) $ (0.81 )
 
Shares used to compute basic and diluted net loss per share   67,397     58,200     64,910     55,707  
 




2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs